Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood test allow uveitis patients to safely take less medication?

NCT ID NCT06390436

Disease control Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial investigates whether people with chronic non-infectious uveitis—an eye condition that can cause blindness—can safely reduce their dose of adalimumab (a drug that calms the immune system) by using regular blood tests to monitor drug levels. Participants whose uveitis has been stable for at least 48 weeks will either continue standard dosing or follow a dose-spacing schedule guided by their blood drug concentration. The goal is to see if the lower-dose strategy is as effective at preventing eye inflammation while potentially reducing side effects and treatment burden.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Adalimumab
What this could lead to
If successful, this could show that many patients with stable uveitis can safely take less adalimumab, reducing side effects and costs without losing disease control.
What could go wrong
This is a Phase 4 trial, so adalimumab is already approved. The main risk is that reducing the dose might lead to a flare-up of uveitis in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed and having signed the study consent form * Age ≥ 18 years * NICU according to the Standardization of Uveitis Nomenclature (SUN) criteria * Complete ophthalmological response for ≥ 48 weeks (96 weeks for uveitis related to Behçet's disease), all treatments combined * On ADA 40mg / 14 days for ≥ 24 weeks (i.e. achievement of the steady state for ADA concentrations) * Not having received systemic corticosteroid therapy for ≥ 12 weeks Exclusion Criteria: * Inability or refusal to understand and/or sign the informed consent form to participate in the study. * Inability and/or refusal to carry out the follow-up examinations required for the study. * Modification of any background immunomodulatory treatment (e.g. methotrexate, hydroxychloroquine, mycophenolate, etc.) associated with ADA, during the 12 weeks prior to inclusion. * Uveitis suspected or proven to be of infectious origin * Planned surgery (or other foreseeable medical event) requiring discontinuation of ADA for the duration of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Disease uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic disease Uveitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHP - Centre hospitalier national des Quinze-Vingts

    Paris, 75012, France

  • APHP - Hôpital Cochin

    Paris, 75014, France

  • APHP - Hôpital Pitié-Salpétrière

    Paris, 75013, France

  • CH Avignon

    Avignon, 84000, France

  • CH Le Puy-en-Velay

    Le Puy-en-Velay, 43000, France

  • CHU Grenoble Alpes

    Grenoble, 38700, France

  • CHU MONTPELLIER - Hôpital Saint-Eloi

    Montpellier, 34090, France

  • Chu Montpied

    Clermont-Ferrand, 63003, France

  • Chu de Saint-Etienne

    Saint-Etienne, 42055, France

  • HCL - Hôpital Edouard Herriot

    Lyon, France

  • Hôpital de la Croix Rousse

    Lyon, 69317, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.